ImageneBio, Inc. (IMA): Revenue
$800.0K
Year ended 2025-12-31
-62.9%
3-year compound annual growth
-38.6%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $800.0K | -77.1% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $3.50M | -61.8% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $9.16M | -41.3% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $15.62M | -49.6% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $30.98M | +237.0% | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $9.19M | n/a | 2022-03-17, From 2020-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | 2025-12-31 | $800.0K | -77.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $893.0K | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | $1.02M | -24.0% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $593.0K | -13.2% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $1.30M | +550.0% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.31M | +99.2% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $1.41M | n/a |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $2.04M | n/a |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $2.19M | -39.5% |
Compare IMA, PROK, PLUR, CRDF side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗